**MedTech Acquisition Announces Leadership Transition and Salary Investment Program**

MedTech Acquisition (OTCMKTS:MTACU) recently disclosed its current report with the Securities and Exchange Commission (SEC) dated January 4, 2025. The report outlined significant updates, primarily involving the appointment of new key executives and the initiation of a salary investment program.

TriSalus Life Sciences, Inc., a subsidiary of MedTech Acquisition, confirmed, effective January 6, 2025, a leadership transition that saw James Young elevated to the position of Chief Financial Officer, Secretary, Treasurer, and principal financial and accounting officer. Concurrently, Sean Murphy assumed the role of Chief Manufacturing, Strategy, and Business Development Officer. Notably, Murphy will continue serving as a member of the Board.

Young, aged 62, formerly held the position of Senior Vice President of Investor Relations and Treasurer at the Company since August 2023. His extensive experience includes a 33-year tenure at Abbott Laboratories, culminating in roles such as Vice President and Chief Ethics and Compliance Officer. A transition agreement, known as the Young Employment Agreement, offers details of his new role, including an annual base salary of $420,000, performance bonuses, and benefits eligibility.

Furthermore, the Company also disclosed an initiative termed the Salary Investment Program on January 4, 2025. The program allows executive officers to opt for reduced annual base salaries in exchange for Restricted Stock Units (RSUs). As of the end of 2024, executives had collectively chosen to invest $515,052 in the program.

The updated executives discussed, Dr. Richard Marshak and Jodi Devlin, have also undertaken elevated roles within TriSalus Life Sciences.

In light of these changes, the Company extended its gratitude to outgoing Chief Financial Officer, Sean Murphy, who is set to play a vital role in business development, manufacturing, strategy, and board membership.

The recent 8-K filing also unveiled detailed agreements regarding the appointments, severance benefits, and indemnity coverage for the transitioning executives. These agreements, along with the leadership changes, are aimed at fortifying the Company’s operational excellence and continuity in leadership.

This seamless transition and program reveal a strategic and proactive approach by MedTech Acquisition to fortify its leadership team and align executive compensation with performance goals.

This press release can be found for additional details and quotes regarding the leadership transition and executive backgrounds.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MedTech Acquisition’s 8K filing here.

About MedTech Acquisition

MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut.